Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Comment by okgonowon Mar 19, 2024 12:56pm
29 Views
Post# 35940914

RE:RE:there is

RE:RE:there is
alleyesonme wrote: The value lies in the suite of licenses and certifications for cannabinoids as a pharmaceutical ingredient in respective jurisdictions...the time to obtain such licenses once the facility is built could range between 2-4 years...now the cost....GW JAZZ announced expansion to the existing extraction facility in the U.K at 100 million price tag...Once a large pharmaceutical Corp reaches the point of commercialization I would expect they would source API from someone like LABS...if the new drug proves commercially successful they could begin building and then wait years for the licences and certs and probably burn 500m...or they could buy a Corp like labs who's presently only worth 28m and turn key...IMO Labs will be bought, this is the end game, and the C suite knows this which is why their enriching themselves with share based compensation to the tune of 30m shares..


ok at what price as i said in a earlier post .25? max at this point i woud think?
<< Previous
Bullboard Posts
Next >>